Cure First, Seattle, WA, USA; SEngine Precision Medicine, Seattle, WA, USA.
SEngine Precision Medicine, Seattle, WA, USA.
Cell Syst. 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003.
Although the MYC oncogene has been implicated in cancer, a systematic assessment of alterations of MYC, related transcription factors, and co-regulatory proteins, forming the proximal MYC network (PMN), across human cancers is lacking. Using computational approaches, we define genomic and proteomic features associated with MYC and the PMN across the 33 cancers of The Cancer Genome Atlas. Pan-cancer, 28% of all samples had at least one of the MYC paralogs amplified. In contrast, the MYC antagonists MGA and MNT were the most frequently mutated or deleted members, proposing a role as tumor suppressors. MYC alterations were mutually exclusive with PIK3CA, PTEN, APC, or BRAF alterations, suggesting that MYC is a distinct oncogenic driver. Expression analysis revealed MYC-associated pathways in tumor subtypes, such as immune response and growth factor signaling; chromatin, translation, and DNA replication/repair were conserved pan-cancer. This analysis reveals insights into MYC biology and is a reference for biomarkers and therapeutics for cancers with alterations of MYC or the PMN.
虽然 MYC 癌基因已被牵涉到癌症中,但缺乏对人类癌症中 MYC、相关转录因子和共调节蛋白(构成近端 MYC 网络 (PMN))改变的系统评估。使用计算方法,我们定义了与 MYC 和 PMN 相关的基因组和蛋白质组特征,跨越了癌症基因组图谱中的 33 种癌症。泛癌分析中,28%的所有样本都至少扩增了一个 MYC 基因家族成员。相比之下,MYC 的拮抗剂 MGA 和 MNT 是最常发生突变或缺失的成员,这表明它们具有肿瘤抑制子的作用。MYC 的改变与 PIK3CA、PTEN、APC 或 BRAF 的改变是相互排斥的,这表明 MYC 是一个独特的致癌驱动因子。表达分析揭示了肿瘤亚型中与 MYC 相关的途径,如免疫反应和生长因子信号;染色质、翻译和 DNA 复制/修复在泛癌中是保守的。这项分析揭示了对 MYC 生物学的深入了解,并且为 MYC 或 PMN 改变的癌症的生物标志物和治疗提供了参考。